AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Meclofenamic acid is effective in reducing pain associated with various conditions, including menstrual cramps, dental pain, musculoskeletal injuries, and postoperative pain.
Inflammation Reduction: It helps to decrease inflammation by inhibiting the production of prostaglandins, which are chemicals in the body that contribute to pain and inflammation.
Rheumatic Conditions: Meclofenamic acid is commonly used to manage symptoms of rheumatic conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It can help reduce joint pain, stiffness, and swelling.
Primary Dysmenorrhea: This medication is often prescribed for the treatment of primary dysmenorrhea (menstrual pain) in women. It can alleviate menstrual cramps and discomfort.
Fever Reduction: Meclofenamic acid can help lower fever by acting on the hypothalamus, the part of the brain that regulates body temperature.
Dosage and Administration: The dosage of meclofenamic acid sodium salt monohydrate may vary depending on the severity of the condition being treated and the individual's response to the medication. It is typically taken orally in the form of tablets or capsules, with or without food. It's important to follow the dosage instructions provided by the healthcare provider.
Side Effects: Common side effects of meclofenamic acid may include gastrointestinal symptoms such as stomach pain, nausea, vomiting, diarrhea, and indigestion. Long-term use or high doses of NSAIDs like meclofenamic acid can increase the risk of gastrointestinal ulcers and bleeding. Other potential side effects include headache, dizziness, drowsiness, rash, and elevated blood pressure.
Cardiovascular Risk: NSAIDs, including meclofenamic acid, may increase the risk of cardiovascular events such as heart attack or stroke, especially in individuals with pre-existing cardiovascular disease or risk factors.
Renal Effects: Prolonged use of meclofenamic acid can affect kidney function and may lead to fluid retention, edema, and decreased urine output. Individuals with impaired renal function or dehydration may be at higher risk of experiencing these effects.
Allergic Reactions: Some individuals may experience allergic reactions to meclofenamic acid, characterized by symptoms such as hives, swelling of the face or throat, difficulty breathing, and anaphylaxis. If any signs of an allergic reaction occur, medical attention should be sought immediately.
Contraindications: Meclofenamic acid is contraindicated in individuals with a history of hypersensitivity to NSAIDs, peptic ulcer disease, gastrointestinal bleeding, severe heart failure, and severe renal impairment. It should be used with caution in patients with asthma, hypertension, or liver dysfunction.
Drug Interactions: Meclofenamic acid may interact with other medications, including anticoagulants, antiplatelet drugs, selective serotonin reuptake inhibitors (SSRIs), and certain diuretics. Patients should inform their healthcare provider about all medications and supplements they are taking to avoid potential interactions.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0 | 0 | |
Acne | 0.2 | -0.2 | |
ADHD | 4.1 | 0.3 | 12.67 |
Age-Related Macular Degeneration and Glaucoma | 0 | 0.5 | 0 |
Allergic Rhinitis (Hay Fever) | 2.4 | 0.5 | 3.8 |
Allergies | 2.6 | 1.7 | 0.53 |
Allergy to milk products | 1.6 | 1 | 0.6 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 3.6 | 2.6 | 0.38 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.8 | 1.87 |
Ankylosing spondylitis | 3.2 | 1.9 | 0.68 |
Anorexia Nervosa | 0.5 | 1 | -1 |
Antiphospholipid syndrome (APS) | 2 | 0 | 0 |
Asthma | 0.5 | 0.5 | 0 |
Atherosclerosis | 0.8 | 1.3 | -0.63 |
Atrial fibrillation | 2 | 2.1 | -0.05 |
Autism | 7 | 5 | 0.4 |
Barrett esophagus cancer | 0.5 | 0.4 | 0.25 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 1.4 | 0.5 | 1.8 |
Brain Trauma | 0.2 | 0.5 | -1.5 |
Carcinoma | 2.5 | 1.8 | 0.39 |
Celiac Disease | 2.2 | 1.8 | 0.22 |
Cerebral Palsy | 0.9 | 0.6 | 0.5 |
Chronic Fatigue Syndrome | 4.6 | 5.3 | -0.15 |
Chronic Kidney Disease | 2 | 0.3 | 5.67 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.5 | 0.3 | 7.33 |
Chronic Urticaria (Hives) | 1.7 | 1.7 | 0 |
Coagulation / Micro clot triggering bacteria | 1.8 | 0.6 | 2 |
Colorectal Cancer | 5.8 | 0.2 | 28 |
Constipation | 1 | 0 | 0 |
Coronary artery disease | 0.9 | 0.3 | 2 |
COVID-19 | 8.7 | 9.1 | -0.05 |
Crohn's Disease | 7.6 | 3.6 | 1.11 |
cystic fibrosis | 0.9 | 0.6 | 0.5 |
deep vein thrombosis | 0.9 | 0.6 | 0.5 |
Depression | 9.1 | 4.7 | 0.94 |
Dermatomyositis | 0.4 | 0.2 | 1 |
Eczema | 1 | 2.6 | -1.6 |
Endometriosis | 2.8 | 0.6 | 3.67 |
Eosinophilic Esophagitis | 0.5 | 0.5 | |
Epilepsy | 2.8 | 2.1 | 0.33 |
Fibromyalgia | 2.3 | 3.3 | -0.43 |
Functional constipation / chronic idiopathic constipation | 4.8 | 3.9 | 0.23 |
gallstone disease (gsd) | 1.4 | 0.7 | 1 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 0.4 | 3.5 |
Generalized anxiety disorder | 2.2 | 1.3 | 0.69 |
giant cell arteritis | 0.4 | -0.4 | |
Glioblastoma | 0.4 | -0.4 | |
Gout | 0.3 | -0.3 | |
Graves' disease | 1.1 | 0 | 0 |
Halitosis | 1 | 0.4 | 1.5 |
Hashimoto's thyroiditis | 0.7 | 0.7 | 0 |
Hidradenitis Suppurativa | 0.9 | 0.9 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.9 | 0.2 | 8.5 |
hypercholesterolemia (High Cholesterol) | 0.9 | 0.9 | |
hyperglycemia | 0.3 | 1.1 | -2.67 |
Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | |
hypersomnia | 0 | 0 | |
hypertension (High Blood Pressure | 2 | 3 | -0.5 |
Hypothyroidism | 0.5 | -0.5 | |
Hypoxia | 1 | 1 | |
IgA nephropathy (IgAN) | 4.9 | -4.9 | |
Inflammatory Bowel Disease | 4.7 | 4.5 | 0.04 |
Insomnia | 0.9 | 0.5 | 0.8 |
Intelligence | 1.7 | 0.7 | 1.43 |
Intracranial aneurysms | 1.1 | 1.1 | |
Irritable Bowel Syndrome | 3.9 | 3.4 | 0.15 |
Liver Cirrhosis | 3.7 | 1.9 | 0.95 |
Long COVID | 6.7 | 4.3 | 0.56 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 1.2 | 0.2 | 5 |
ME/CFS with IBS | 0.8 | 1.3 | -0.63 |
ME/CFS without IBS | 1.6 | 1.7 | -0.06 |
Menopause | 1.3 | 1.3 | |
Metabolic Syndrome | 6.9 | 6 | 0.15 |
Mood Disorders | 10.3 | 4.7 | 1.19 |
multiple chemical sensitivity [MCS] | 1.1 | 0 | 0 |
Multiple Sclerosis | 3.4 | 5.3 | -0.56 |
Multiple system atrophy (MSA) | 1 | 0.4 | 1.5 |
Neuropathy (all types) | 0.4 | 0.3 | 0.33 |
neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 2 | -0.11 |
NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
Obesity | 5.4 | 3.6 | 0.5 |
obsessive-compulsive disorder | 6.8 | 2.9 | 1.34 |
Osteoarthritis | 2.6 | 0.2 | 12 |
Osteoporosis | 1.3 | 0.5 | 1.6 |
pancreatic cancer | 0.9 | 0.9 | |
Parkinson's Disease | 2 | 2.7 | -0.35 |
Polycystic ovary syndrome | 2.1 | 1.3 | 0.62 |
Postural orthostatic tachycardia syndrome | 0.4 | 0.5 | -0.25 |
Premenstrual dysphoric disorder | 0.2 | 0.5 | -1.5 |
primary biliary cholangitis | 0 | 1 | 0 |
Psoriasis | 2.8 | 2.9 | -0.04 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.8 | 3.3 | 0.45 |
Rosacea | 0.4 | 0.4 | 0 |
Schizophrenia | 4.5 | 1 | 3.5 |
scoliosis | 0.3 | 0.2 | 0.5 |
Sjögren syndrome | 2.4 | 2.5 | -0.04 |
Sleep Apnea | 1.1 | 0.8 | 0.38 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 1.5 | |
Stress / posttraumatic stress disorder | 2.6 | 0.9 | 1.89 |
Systemic Lupus Erythematosus | 4.7 | 0.8 | 4.88 |
Tic Disorder | 0.9 | 0.9 | 0 |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 3.5 | 1.4 | 1.5 |
Type 2 Diabetes | 6.9 | 6.7 | 0.03 |
Ulcerative colitis | 2.5 | 5.3 | -1.12 |
Unhealthy Ageing | 5.6 | 1 | 4.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.